

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/013930 A1

(51) International Patent Classification⁷: **A61K 7/40**,
A61P 33/14, A01N 53/00, 31/02, 55/00 // (A01N 55/00,
65:00, 43:36, 43:16, 37:04, 25:30) (A01N 31/02, 65:00,
43:36, 43:16, 37:04, 25:30) (A01N 53/00, 65:00, 43:36,
43:16, 37:04, 25:30)

(21) International Application Number:
PCT/GB2004/003297

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0318160.9 2 August 2003 (02.08.2003) GB

(71) Applicant (for all designated States except US): **SSL IN-
TERNATIONAL PLC** [GB/GB]; 35 New Bridge Street,
London EC4V 6BW (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **DOKIC-GAL-
LAGHER, Jasmina** [—/GB]; 42 Haniwells, 20 Hender-
son Street, Manchester (GB).

(74) Agents: **GOODWIN, Mark** et al.; Wilson Gunn M'Caw,
5th Floor, Blackfriars House, The Parsonage, Manchester
M3 2JA (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PARASITICIDAL COMPOSITION

(57) Abstract: A parasiticide composition comprising, as an active ingredient, at least one bioadhesive polymer and salts thereof together with at least one physiologically acceptable carrier.



WO 2005/013930 A1

Parasitocidal Composition

The present invention relates to a parasitocidal composition which finds particular utility in the control of head lice infestation in humans.

Lice infestation in humans is generally caused by insects from the families
5 *Pediculidae* and *Phthiridae*, in particular *Pediculus humanus* species and *Phthirus pubis*.
Head lice infestations are caused in particular by *Pediculus humanus capitis*.

The control of parasite infestation such as head lice has recently been managed by mosaic policies, with insecticides from the group consisting of dichlorodiphenyl trichloroethane (DDT), cyclodienes, organophosphates, carbamates and pyrethyroids
10 as well as 'herbal' remedies such as tea-tree oil or other naturally derived terpenoid sources.

Head lice are known to become resistant to treatments, thus, to ensure availability of a diversity of insecticidal treatments there is a continuing requirement for novel insecticides to ensure suitable mosaic policies are maintained.

15 It is an object of the present invention to seek to provide alternative novel insecticides for the treatment of head lice.

According to a first aspect of the present invention there is provided a parasitocidal composition comprising as an active ingredient at least one bioadhesive polymer and salts thereof together with at least one physiologically acceptable carrier.

20 Surprisingly, it has been found that bioadhesive polymers are highly effective in killing parasites and in particular those parasites responsible for head lice infestation. Thus, bioadhesive polymers have been found to have pediculicidal (that is, they kill lice) and ovicidal (that is, they kill lice eggs) activity.

As referred to herein the term bioadhesive polymers, includes but is not limited to, carbomer related substances, natural gums, thickeners, gelling agents and cellulose derivatives.

Preferably, the bioadhesive polymer constitutes from 0.25 to 10 % w/w of the
5 total composition.

Preferably, the bioadhesive polymers of the present invention are carbomer related substances (hereinafter referred to as carbomer(s)). Carbomers are high molecular weight network polymers consisting of acrylic acid backbones cross linked with polyalkenyl ethers. Typically carbomers have a molecular weight in the range of
10 from 700 000 to 3-4 billion.

Where the bioadhesive polymer is a carbomer the said substance shall preferably constitute from 0.25 to 2.0% w/w of the total composition.

The physiologically acceptable carrier may be any suitable chemical entity that is compatible with human physiology and the bioadhesive polymer.

15 Examples of suitable physiologically acceptable carriers, which may be used alone or in combination, include alcohols such as isopropanol (IPA), ethanol and industrial methylated spirit (IMS), water and silicone based compounds such as cyclomethicone.

Generally, where present water constitutes a maximum of 99.75% w/w of the
20 total composition.

Where the composition comprises more than one physiologically acceptable carrier, water may be added up to 100% w/w.

The composition of the present invention may further comprise at least one surfactant selected from any of the following either alone or in combination: anionic, cationic, non-ionic, amphoteric or zwitterionic agents.

The anionic surfactants may be selected from any of the following either alone
5 or in combination: monovalent alkyl carboxylates, polyvalent alkyl carboxylates, acyl lactylates, alkyl ether carboxylates, N-acyl sarcosinates, N-acyl glutamates, fatty acid-polypeptide condensates, sulphuric acid esters, ester-linked sulphonates, alpha olefin sulphonates and phosphated ethoxylated alcohols.

The cationic surfactants may be selected from any of the following either
10 alone or in combination: monoalkyl and dialkyl quaternary ammonium compounds, amidoamines and aminimides.

The non-ionic surfactants may be selected from any of the following either alone or in combination: polyoxyalcohols, polyoxypropylenes, amine oxides, fatty acid esters and polyhydric alcohols.

15 The amphoteric/zwitterionic surfactants may be selected from any of the following either alone or in combination: triglycerides, e.g. lecithin, N-substituted alkyl amides, N-alkyl betaines, sulphobetaines and N-alkyl beta aminopropionates.

The aforementioned surfactants may also impart emulsifying properties to the composition of the present invention.

20 Preferably the pH of the composition of the present invention is in the range from 4.5 to 8.0.

The composition of the present invention may include additional ingredients, for example co-monomers such as C₁₀ – C₃₀ alkyl acrylates. These alkyl acrylates are

used to hydrophobically modify homopolymer carbomers to improve their electrolyte tolerance.

In one embodiment of the present invention the composition comprises from 0.25 to 1.0% w/w carbomer together with up to 10% w/w of a cyclicsiloxane or an
5 hydroxy-terminated linear siloxane. Preferably, the cyclic siloxane is decamethylcyclopentasiloxane.

In a further embodiment of the present invention the composition comprises from 0.25 to 1.0% w/w carbomer together with up to 60% w/w of an alcohol
10 component. Preferably, the alcohol component is IPA which constitutes from 10 to 30% w/w.

In a further embodiment of the present invention the composition comprises from 0.25 to 1.0% w/w of carbomer together with up to 10% w/w of a silicone component and from 10 to 30% w/w of IPA.

In a still further embodiment of the present invention the composition
15 comprises from 0.25 to 1.0% w/w of carbomer together with at least one surfactant and IPA.

The composition of the present invention may further comprise a component having additional ovicidal activity. Such constituents result in the destruction of louse eggs even when the composition is in contact with hair for a relatively short period of
20 time

Suitable ovicidal agents include terpenes and terpenoids such as those referred to in WO 00/64265, preferably one or both of d-limonene and geranyl acetate.

The composition of the present invention may be combined with at least one other pediculicidal and/or ovicidal agent such as d-phenothrin, malathion, carbaryl as

well as natural ingredients such as tea tree oil and neem oil. Such agents may act synergistically with the composition of the present invention such that the efficacy of the composition is enhanced.

In a still further embodiment of the present invention the composition
5 comprises carbomer, surfactant, IPA and a component which delivers ovicidal activity.

The composition of the present invention is thought to form a bioadhesive polymer network on the surface of the louse and egg. Thus, the composition is thought to be acting by suffocation and/or affecting water/electrolyte elimination or
10 retention in the louse/eggs i.e. osmoregulation.

According to the second aspect of the present invention there is provided a bioadhesive polymer for use in the treatment of lice in humans.

According to the third aspect of the present invention there is provided the use of at least one bioadhesive polymer in the preparation of a composition for the
15 treatment of lice in humans.

According to the fourth aspect of the present invention there is provided a process for the preparation of a parasitocidal composition as hereinbefore defined comprising the step of: bringing together at least one bioadhesive polymer and salts thereof and at least one physiologically acceptable carrier.

20 Preferably, the composition of the present invention is adapted for topical application to a subject.

Therefore, the composition of the present invention may be provided in any suitable form to allow such application, for example a gel, lotion, liquid, mousse

(aerosol and non-aerosol), shampoo, crème rinse, serum, spray or emulsion for the hair.

Unless otherwise stated, all quantities referred to herein are measured by weight of the total composition.

5 The present invention will now be described further by way of example only with reference to the following experimental results.

Method of Testing the Pediculicidal/Ovicidal Activity of a Composition

Samples of Carbopol® Ultrez 21 (manufactured by Noveon, Inc. and stated to be a
10 hydrophobically modified cross-linked polyacrylate polymer) were used as an example of carbomers. Other carbomers may include but are not limited to Carbopol® Ultrez 10, Carbopol® ETD 2020 and 2050, Carbopol® 980, 981, 971, 71G 1382, 2984, 5984, 934, 940, 941, 1342.

15 The selected carbomer was wetted with water and then dispersed in additional water, using a high shear mixer with, to form a gel or solution with the appropriate % w/w carbomer content. Finally, pH was adjusted to pH 4.5 to pH 8.0; preferably pH 5.0 to pH 6.0, with NaOH solution or triethanolamine.

20 Measurement of Activity by Immersion

Human lice, *Pediculus humanus*, were tested by Insect R&D Limited, Cambridge, UK. Adult female and male lice, in approximately equal numbers, were used for each test. The lice were fed on the morning of the test and allowed a minimum of 4 hours to recover, during which time they were able to excrete excess

water imbibed with their blood meal. Lice were counted into batches that were provided with squares of open meshed nylon gauze (tulle), as a substrate upon which to stand, and each batch allocated to a marked 30-millimeter plastic Petri dish.

Louse eggs, *Pediculus humanus*, were tested by Insect R&D Limited, Cambridge, UK. They were obtained by providing actively laying adult lice with a close meshed nylon substrate, in place of the normal cotton corduroy substrate, over a 48 hour period. At the end of this time the insects were removed and the gauze cut into appropriately sized smaller pieces. The small gauze pieces were randomly allocated to plastic Petri dishes in advance of the test.

For the test procedure an aliquot of approximately 5 millilitres of test solution was poured onto the base of a clean 30 millimetre plastic Petri dish. The gauze bearing the lice/eggs was immersed in the fluid for 10 seconds, during which time the gauze was turned at least twice to ensure removal of air bubbles. After removal from the fluid the gauze and eggs were lightly blotted to remove any excess and returned to the marked Petri dish. In the case of gels, an aliquot of approximately 5 millilitres of gel was placed on the palm of the hand and the lice/eggs gently rubbed in the gel for 10 seconds. Hands were washed thoroughly between test gels.

Gauze squares bearing lice/eggs were incubated under normal maintenance conditions ($30^{\circ} \pm 2^{\circ}$ Celsius and $50\% \pm 15\%$ relative humidity) for the remainder of the test period. At the end of the appropriate time the lice/eggs were washed for 30 seconds, using a 1: 15 mixture of Boots® frequent wash shampoo in tap water, and rinsed three times in warm (35° Celsius) tap water, poured over and through the gauze, followed by blotting with a medical wipe tissue. The gauze squares with their lice/eggs were then incubated under normal maintenance conditions until the results

were recorded. Observations of the mortality of the lice were recorded after 24 hours and of louse eggs when the control group had completed emergence, a minimum of 10 days after treatment.

For most tests, lice and eggs were exposed to the treatment overnight.
5 However, the effects of different exposure times, from 10 minutes to 8 hours, were also assessed for some test formulations.

A control comparison test was performed using 60% propan-2-ol (isopropanol), which is routinely used in our laboratory and causes minimum mortality to lice, in place of carbomer gels. All other procedures for this comparator
10 were the same as for the test groups. The IPA control test was usually run at the end of each set of tests, but was also occasionally run at the beginning as well as at the end of a set of tests.

Results

15 Medical grade materials (or National Formulary, NF, grade) were used where available.

Example 1

20 Carbopol® Ultrez 21 was wetted with water, and then dispersed in further water to form a gel containing 0.5% w/w carbomer. The pH of the gel was adjusted to a pH of 5.0 and 6.0. The pediculicidal and ovicidal efficacy of the gel was then assessed according to the Measurement of Activity by Immersion test method already

described, following overnight exposure. Most dead lice had burst guts so that they took on a dark red colour throughout the tissue.

Percent pediculicidal efficacy was calculated from the formula:

$$PE = \frac{L_{Dead} + L_{Moribund}}{L_{Total}} \times 100\% \quad \text{OR} \quad PE = \frac{L_{Total} - L_{Alive}}{L_{Total}} \times 100\%$$

where: L_{Dead} = number of lice assessed as dead at end of exposure period

$L_{Moribund}$ = number of lice assessed as moribund at end of exposure period ('moribund' includes any state in which the insect is deemed to be non-viable and unlikely to continue life at the time of observation; such insects may show only the slightest of movements of a limb or part of the gut but the category extends through walking insects that are considered sufficiently lacking in co-ordination that they would be unable to hold onto their substrate, feed or lay eggs)

L_{Total} = total number of lice exposed to test formulation

L_{Alive} = number of lice assessed as alive and viable at end of exposure period

PE = percent mortality or uncorrected pediculicidal efficacy

Percent ovicidal efficacy was calculated from the formula:

$$OE = \frac{O_{Undeveloped} + O_{Dead} + O_{Half-hatched}}{O_{Total}} \times 100\% \quad \text{OR}$$

$$OE = \frac{O_{Total} - O_{Hatched}}{O_{Total}} \times 100\%$$

5

where: $O_{Undeveloped}$ = number of eggs assessed as undeveloped (not hatched) at end of exposure period

O_{Dead} = number of eggs in which the embryo died (as shown by the lack of eye-spot or malformed eye-spot)

10 $O_{Half-hatched}$ = number of eggs from which a louse was killed whilst emerging from the egg

O_{Total} = total number of eggs exposed to test formulation

$O_{Hatched}$ = number of eggs that hatched successfully

OE = percent mortality or uncorrected ovicidal efficacy

15

Efficacy percentages were corrected using Abbott's formula (*A method of computing the effectiveness of an insecticide*, Abbott WS, Journal of Economic Entomology, **18**; pp 265-7 (1925)). This is a simple formula used to adjust observed test mortality data to allow for any mortality in control groups:

20

$$PE_C \text{ or } OE_C = \frac{T - C}{100 - C} \times 100\%$$

where: PE_C = corrected percent pediculicidal efficacy or mortality

OE_C	=	corrected percent ovicidal efficacy or mortality
T	=	uncorrected percent efficacy in test group
C	=	uncorrected percent efficacy in control group

5 In the following Tables, all pediculicidal or ovicidal efficacy data under "Mortality (%)” are the corrected pediculicidal or ovicidal data. Differences between lice and eggs from different batches and within different batches mean that the results from any particular assessment can be subject to about a 10% error. Therefore all efficacy results have been rounded to the nearest 10% where appropriate.

10

The pediculicidal efficacy results for 0.5% Ultrez 21 are given in Table 1. It was found to be 100% effective after overnight treatment.

Examples 2-9a

15

The efficacy of a range of carbomers was evaluated by preparing formulations containing between 0.05% w/w to 2.0% w/w carbomer, in water and adjusting the pH of the resulting mix to between pH 5.0 to pH 6.0. Although gels containing more than 2.0% w/w carbomer were made and were 100% effective, their high viscosity made
20 them unsuitable for use without adjustment of the formulation by the addition of appropriate diluents to reduce the viscosity of the gel to a suitable level.

Although 0.05%w/w carbomer showed some efficacy against lice overnight, this was considered too low to provide an effective product. However, levels of 0.25%w/w

and above were totally effective against lice overnight. 1.0% carbomer was totally effective after only 2 hours and 60% effective after only 10 minutes. In all cases, the IPA controls showed between 10-30% efficacy against lice overnight (average of 20%).

5

Table 1: Pediculicidal efficacy of a range of carbomers

	Carbomer	% w/w	Time	Mortality (%)
Example 2	Ultrez Polymer 10	0.05	overnight	30
Example 3	Carbopol 980NF	0.05	overnight	30
Example 4	Ultrez Polymer 10	0.25	overnight	100
Example 5	Carbopol 980NF	0.25	overnight	100
Example 1	Ultrez Polymer 21	0.5	overnight	100
Example 6	Ultrez Polymer 10	0.5	overnight	100
Example 7	Carbopol 980NF	0.5	overnight	100
Example 8	Carbopol 980NF	1.0	overnight	100
Example 9	Ultrez Polymer 10	1.0	10 minutes	60
Example 9a	Ultrez Polymer 10	2.0	overnight	100
Control (60% IPA)	Control (60% IPA)	-	overnight	20

Examples 10-16

10

A range of other bioadhesive polymers was evaluated for pediculicidal efficacy, using the same procedure as outlined previously for the evaluation of the carbomers. The results of the assessment are given in Table 2.

The viscosity modifying properties of the various polymers are different and therefore some can be used at much higher concentrations to achieve similar gels to the other polymers. As can be seen from the results, it was possible to formulate

5 pediculicidally effective gels from all of the bioadhesive polymers evaluated.

Table 2: Pediculicidal efficacy of a range of bioadhesive polymers

	Polymer	% w/w	Time	Mortality (%)
Example 1	Ultrez 21	0.5	overnight	100
Example 10	CMC-7HF ¹	2.0	overnight	70
Example 11		4.0	overnight	100
Example 12	Kollidon® 90F ²	4.0	overnight	60
Example 12a		10.0	overnight	100
Example 13	Tragacanth ³	2.0	overnight	90
Example 14	Methocel E15LV ⁴	4.0	overnight	60
Example 14a		10.0	overnight	100
Example 15	Polycarbophil AA1 ⁵	1.0	overnight	100
Example 16	Guar gum ⁶	0.5	overnight	100
Control (60% IPA)	Control (60% IPA)	-	overnight	20

¹ CMC-7HF - sodium carboxymethylcellulose gum from Hercules, Inc

² Kollidon® 90F - polyvinylpyrrolidone from BASF, Inc.

10 ³ Tragacanth gum - complex mixture of acidic polysaccharides (available from ISP Food Specialties (UK) Ltd)

⁴ Methocel® E15LV - cellulose methyl ether from Dow Chemical Inc

⁵ Polycarbophil AA1 - a copolymer of acrylic acid and divinylglycol, from Noveon Inc

15 ⁶ Guar Gum - polysaccharides based on galactomannan (available from Thew Arnott & Co Ltd)

Examples 17-22

It has been found that a number of process aids can enhance the efficacy of the
5 bioadhesive polymers' gels, and in particular the carbomer gels. For example, the
inclusion of an alcohol in the formulation, or a cyclic silicone, can both lead to
enhanced pediculicidal and/or ovicidal efficacy.

The gels were prepared as previously except that the cyclomethicone or IPA was
10 added before or after the addition of the carbomer to the water, but before the pH was
adjusted. The gels were tested as previously described and the results for
pediculicidal efficacy are given in Table 3 and for ovicidal efficacy in Table 4.

15

20

Table 3: Pediculicidal efficacy of including alcohol or cyclic siloxane

Component	Formulation (% w/w)					Control
	Example 8	Example 17	Example 18	Example 18a	Example 19	
Carbomer	1.0	1.0	1.0	1.0	1.0	60% IPA
ST-cyclomethicone 5	-	10.0	-	-	-	
IPA	-	-	20.0	30.0	60.0	
% Efficacy at 10 minutes	60	100	-	-	-	-
% Efficacy at 2 hours	-	-	-	80	100	-
% Efficacy at 4 hours	-	-	-	-	-	-
% Overnight efficacy	100	-	100	-	-	20

ST-cyclomethicone 5 (from Dow Corning) = decamethylcyclopentasiloxane

- 5 The addition of 10%w/w cyclomethicone (Example 17) improved the 100% efficacy time for 1.0% w/w carbomer from overnight to about ten minutes. IPA on the other hand has little impact at relatively low IPA levels (up to at least 20% w/w) whereas high levels of IPA (at least 60% w/w) lead to a significant increase in pediculicidal efficacy.

Table 4: Ovicidal efficacy of including alcohol

Component	Formulation (% w/w)			Control
	Example 20	Example 21	Example 22	
Carbomer	2.0	1.0	1.0	60% IPA
IPA	-	20.0	60.0	
% Efficacy at 2 hours	-	-	30	10
% Overnight efficacy	30	30	-	20

As can be seen, 2.0% w/w carbomer on its own has only 30% ovicidal efficacy overnight. The addition of low levels of IPA (up to at least 20% w/w) to 1% w/w carbomer gel maintained the efficacy seen at the higher carbomer level, and higher
5 carbomer gel maintained the efficacy seen at the higher carbomer level, and higher levels of IPA (of up to 60% w/w) improved the ovicidal efficacy still further.

Examples 23-25

10 The impact of using both an alcohol and a cyclic siloxane in the carbomer gel formulation was also assessed.

15

20

25

Table 5: Pediculicidal efficacy of including alcohol and cyclic siloxane

Component	Formulation (%w/w)				Control
	Example 1	Example 23	Example 24	Example 25	
Carbomer	0.5	0.5	1.0	1.0	60% IPA
ST-cyclomethicone 5	-	10.0	5.0	8.0	
Isopropanol (IPA)	-	20.0	30.0	20.0	
% Efficacy at 10 minutes	-	-	-	100	-
% Efficacy at 2 hours	-	100	100	-	-
% Efficacy at 4 hours	-	-	-	-	-
% Overnight efficacy	100	-	-	-	20

As can be seen from Table 5, the inclusion of 10% w/w cyclic siloxane and 20% w/w IPA to 0.5% carbomer gel improved the 100% efficacy time from overnight to 2 hours. The 100% efficacy time was reduced further, to 10 minutes by increasing the carbomer level to 1.0% w/w and incorporating 8% w/w cyclic siloxane and 20% w/w IPA.

Example 26-30

Gels were prepared containing 0.5%w/w D-Phenothrin to evaluate the pediculicidal and ovicidal efficacies of gels containing a range of bioadhesive polymers.

Table 6: Pediculicidal and ovicidal efficacy of formulations containing D-Phenothrin

	Formulation (% w/w)					Control
Component	Example 26	Example 27	Example 28	Example 29	Example 30	
CMC 7MF	4.0	-	-	-	-	60% IPA
Kollidon® 90F	-	10.0	-	-	-	
Methocel® E15LV	-	-	10	-	-	
Polycarbophil AA1	-	-	-	1	-	
Guar gum	-	-	-	-	1	
ST-cyclomethicone 5	-	-	5	-	-	
Isopropanol (IPA)	-	-	10	-	-	
Propylene glycol	10	10	-	10	10	
D-Phenothrin	0.5	0.5	0.5	0.5	0.5	
% Pediculicidal and ovicidal efficacy [overnight]						
Pediculicidal	100	100	100	100	100	20
Ovicidal	100	100	100	100	100	10

5 Examples 31-35

The pH of the gel formulation was varied from pH 4.5 to pH 8.0 to assess whether pH had an impact on pediculicidal or ovicidal efficacy. The results are given in Table 7

Table 7: Effect of pH on pediculicidal and ovicidal efficacy of carbomer gels

	Formulation (% w/w) and pH					Control
Example	31	32	33	34	35	
Component	pH4.5	pH5.0	pH6.0	pH7.0	pH8.0	
Carbomer	0.5					60% IPA
SLS	0.05					
IPA	10.0					
% Pediculicidal and ovicidal efficacy [overnight]						
Pediculicidal	100	100	100	100	100	10
Ovicidal	70	90	100	100	80	10

SLS = sodium lauryl sulphate (an anionic surfactant)

As can be seen from the results, changing the pH from pH4.5 to pH8.0 had no impact on the pediculicidal efficacy of the carbomer gel though the ovicidal efficacy is optimal between pH 5 to pH 7.

Examples 36-38

- 10 The efficacy of gels containing 0.5% w/w carbomer can also be enhanced by the addition of a surfactant to the gel. Addition of 0.05% w/w SLS (sodium lauryl sulphate) or 5.0% w/w Softigen® 767 (PEG-6 caprylic/capric glyceride, Hüls (UK) Ltd) enhances the ovicidal efficacy of 0.5% w/w carbomer to 100% overnight.

Table 8: Pediculicidal and ovicidal efficacy of carbomer gels containing a surfactant

Component	Formulation (% w/w)			Control
	Example 36	Example 37	Example 38	
Carbomer	0.5	0.5	0.5	60% IPA
SLS	-	-	0.05	
Softigen [®] 767	-	5.0	-	
ST-cyclomethicone 5	-	-	-	
IPA	-	1	10	
% Pediculicidal efficacy [overnight]	100	100	100	20
% Ovicidal efficacy [overnight]	-	100	100	10

5

Formulations

Formulations that can be prepared in accordance with this invention include hair gels, lotions, liquids, mousses (aerosol and non-aerosol), shampoos, crème rinses, sprays or emulsion for the hair treatments. The precise nature and qualities of additional constituents that are required will vary according to the desired properties of the final product. The skilled formulator will be familiar with such constituents and their usage, which can include but it is not limited to, for example, silicone compounds, suspending agents, emulsifying agents, surfactants, foaming agents and foam boosters, alcohol, emollients, preservatives, colourings and perfumes.

To enhance activity of the compositions according to the invention it has been found that further constituents having ovicidal activity can be added without adversely affecting their efficacy. These further constituents are terpenes and in

particular, the terpenes d-limonene and geranyl acetate can be used, each at a concentration of from 0.2% v/v to 1% v/v.

It is of course to be understood that the invention is not intended to be restricted to the details of the above embodiments which are described by way of
5 example only.

Claims

1. A parasitocidal composition comprising, as an active ingredient, at least one bioadhesive polymer and pharmaceutically acceptable salts thereof together with at least one physiologically acceptable carrier.
- 5 2. A composition according to claim 1, wherein the bioadhesive polymer constitutes from 0.25 to 10% w/w of the total composition.
3. A composition according to claim 1 or claim 2, wherein the bioadhesive polymer is a carbomer related substance.
4. A composition according to claim 3, wherein the carbomer related substance
10 constitutes from 0.25 to 2.0% w/w of the total composition.
5. A composition according to any one of the preceding claims wherein the physiological carrier is selected from any of the following either alone or in combination: alcohols, water and silicone based compounds.
6. A composition according to claim 5, wherein the alcohols are selected from
15 any of the following either alone or in combination: isopropanol, ethanol and industrial methylated spirit.
7. A composition according to claim 5, wherein the silicone based compounds are selected from any of the following either alone or in combination: cyclomethicone, hydroxy-terminated linear siloxane.
- 20 8. A composition according to any one of the preceding claims, wherein the composition further comprises at least one surfactant.
9. A composition according to claim 8, wherein the surfactant comprises an anionic surfactant which is selected from any of the following either alone or in combination: monovalent alkyl carboxylates, polyvalent alkyl carboxylates, acyl

lactylates, alkyl ether carboxylates, N-acyl sarcosinates, N-acyl glutamates, fatty acid-polypeptide condensates, sulphuric acid esters, ester-linked sulphonates, alpha olefin sulphonates, phosphated ethoxylated alcohols.

10. A composition according to claim 8, wherein the surfactant comprises a
5 cationic surfactant which is selected from any of the following either alone or in combination: monoalkyl and dialkyl quaternary ammonium compounds, amido amines and aminimides.

11. A composition according to claim 8, wherein the surfactant comprises a non-ionic surfactant which is selected from any of the following either alone or in
10 combination: polyoxyalcohols, polyoxypropylenes, amine oxides, fatty acid esters and polyhydric alcohols.

12. A composition according to claim 8, wherein the amphoteric/zwitterionic is selected from any of the following either alone or in combination: lecithin, N-substituted alkyl amides, N-alkyl betaines, sulfo betaines and N-alkyl beta
15 aminopropionates.

13. A composition according to any one of the preceding claims, wherein the pH of the composition is in the range from 4.5 to 8.0.

14. A composition according to any one of the preceding claims, wherein the composition further comprises co-monomers,

20 15. A composition according to claim 14, wherein the co-monomers are C₁₀-C₃₀ alkyl acrylates.

16. A composition according to any one of the preceding claims, wherein the composition further comprises at least one additional component having ovicidal activity.

17. A composition according to claim 16, wherein the additional component having ovidical activity is selected from any of the following either alone or in combination: terpenes, d-phenothrin, malathion, carbaryl, tea tree oil and neem oil.
18. A composition according to any one of the preceding claims, wherein the
5 composition comprises 0.25 to 1.0% w/w carbomer together with up to 10% w/w of a cyclic siloxane.
19. A composition according to claim 18, wherein the cyclicsiloxane is decamethyl cyclopentasiloxane.
20. A composition according to any one of claims 1 to 15, wherein the
10 composition comprises from 0.25 to 1.0% w/w carbomer together with up to 60% w/w of an alcohol component.
21. A composition according to claim 20, wherein the alcohol component is IPA.
22. A composition according to claim 20 or claim 21, wherein the alcohol constitutes from 10 to 30% w/w of the total composition.
- 15 23. A composition according to any one of claims 1 to 15, wherein the composition comprises from 0.25 to 1.0 w/w carbomer together with up to 10% w/w of a silicone component and from 10 to 30% w/w of IPA.
24. A composition according to any one of claims 1 to 15, wherein the composition comprises from 0.25 to 1.0 w/w carbomer together with at least one
20 surfactant and IPA.
25. A composition according to any one of claims 1 to 17, wherein the composition comprises at least one carbomer, at least one surfactant, IPA and an additional component which delivers ovidical activity.

26. A bioadhesive polymer for use in the treatment of lice in humans.
27. A bioadhesive polymer for use in the preparation of a composition for the treatment of lice in humans.
28. A process for the preparation of a parasitocidal composition as described in
5 claim 1, comprising the steps of: bringing together at least one bioadhesive polymer, and salts thereof, and at least one physiologically acceptable carrier.

10

15

20

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003297

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/40 A61P33/14 A01N53/00 A01N31/02 A01N55/00
 //(A01N55/00,65:00,43:36,43:16,37:04,25:30),(A01N31/02,65:00,43:36
 43:16,37:04,25:30),(A01N53/00,65:00,43:36,43:16,37:04,25:30)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/25544 A (BROWN THOMSEN JOHN ; MOELLER JENS CHRISTIAN (DK)) 28 September 1995 (1995-09-28) claims; examples 1-10,15 -----	1-28
X	GB 2 222 949 A (EURO CELTIQUE SA) 28 March 1990 (1990-03-28) the whole document -----	1-28
X	GB 2 222 774 A (EURO CELTIQUE SA) 21 March 1990 (1990-03-21) claims 1,18-31,40; examples ----- -/--	1-6,8, 11,13, 16,17, 20,21, 24-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

19 November 2004

Date of mailing of the international search report

03/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Minas, S

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003297

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97/15314 A (MARSHALL UNIVERSITY RESEARCH C) 1 May 1997 (1997-05-01) page 12, line 18; claims 1-3,12-14 -----	1-5,16, 26-28
X	WO 01/89503 A (EFFCON LAB INC ; PING JEFFREY H (US)) 29 November 2001 (2001-11-29) page 19, line 21 - line 25; claims; examples; tables -----	1-6,8,9, 11, 13-17, 20-22, 24-28
X	WO 01/50994 A (BURKETT DOUGLAS D ; ZILA INC (US)) 19 July 2001 (2001-07-19) page 16, paragraph 3; claims 1-3; examples -----	1-6,16, 26-28
X	WO 00/64265 A (WILKINSON JOHN ALFRED) 2 November 2000 (2000-11-02) cited in the application claims 7,8 -----	1-28
X	EP 0 468 721 A (UNILEVER PLC ; UNILEVER NV (NL)) 29 January 1992 (1992-01-29) claims; examples -----	1-5,7-9, 11-13, 18,26-28
X	US 2001/051143 A1 (FEWKES KIMBERLY A ET AL) 13 December 2001 (2001-12-13) claims; examples II,III,V; table 2 -----	1,2,5,8, 9,11,13, 26-28
X	US 2002/035161 A1 (SEGURA SANDRINE ET AL) 21 March 2002 (2002-03-21) example 3 -----	1-5,7,8, 13-15, 18,26-28
P,X	US 6 607 716 B1 (CHRISTENSEN JOHN MARK ET AL) 19 August 2003 (2003-08-19) column 5, line 52 - column 6, line 57; claims; examples 1,2,1A,6,7 -----	1-5,8,9, 12,13, 16,26-28
A	WO 02/074088 A (ENTOMOS SCIENCES LTD; BURGESS IAN F ; ANSELL JAYNE (GB)) 26 September 2002 (2002-09-26) page 4, paragraph 3 page 6, line 12; claim 9 -----	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2004/003297

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9525544	A	28-09-1995	AT 208212 T	15-11-2001
			AU 701872 B2	11-02-1999
			AU 2109995 A	09-10-1995
			BR 9507164 A	09-09-1997
			CA 2186045 A1	28-09-1995
			CN 1146725 A	02-04-1997
			CZ 9602723 A3	11-06-1997
			CZ 288150 B6	16-05-2001
			DE 69523745 D1	13-12-2001
			DE 69523745 T2	08-08-2002
			DK 751789 T3	08-09-2003
			EE 3293 B1	16-10-2000
			WO 9525544 A1	28-09-1995
			EP 0751789 A1	08-01-1997
			ES 2168111 T3	01-06-2002
			FI 963696 A	07-11-1996
			HU 9602583 A	28-11-1996
			JP 3560977 B2	02-09-2004
			JP 9510468 T	21-10-1997
			NO 963971 A	19-11-1996
			PL 316651 A1	03-02-1997
			PT 751789 T	29-04-2002
			RU 2142273 C1	10-12-1999
			SI 751789 T1	31-08-2002
			SK 119496 A3	04-06-1997
			US 2002086905 A1	04-07-2002
			US 6342537 B1	29-01-2002
			US 2004054015 A1	18-03-2004
			US 5981605 A	09-11-1999
GB 2222949	A	28-03-1990	NONE	
GB 2222774	A	21-03-1990	NONE	
WO 9715314	A	01-05-1997	US 5741525 A	21-04-1998
			AU 7481996 A	15-05-1997
			EP 0862441 A1	09-09-1998
			WO 9715314 A1	01-05-1997
			US 5958461 A	28-09-1999
WO 0189503	A	29-11-2001	AU 7487701 A	03-12-2001
			WO 0189503 A1	29-11-2001
WO 0150994	A	19-07-2001	WO 0150994 A1	19-07-2001
			CA 2366411 A1	19-07-2001
			EP 1176933 A1	06-02-2002
			JP 2003519641 T	24-06-2003
			NO 20014444 A	09-11-2001
WO 0064265	A	02-11-2000	AU 4420400 A	10-11-2000
			EP 1185178 A2	13-03-2002
			WO 0064265 A2	02-11-2000
EP 0468721	A	29-01-1992	AT 116841 T	15-01-1995
			AU 639351 B2	22-07-1993
			AU 8118291 A	30-01-1992
			BR 9103132 A	05-05-1992
			CA 2047105 A1	24-01-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2004/003297

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0468721	A	DE 69106618 D1	23-02-1995
		DE 69106618 T2	18-05-1995
		EP 0468721 A1	29-01-1992
		ES 2067873 T3	01-04-1995
		GB 2246575 A	05-02-1992
		IN 173461 A1	14-05-1994
		JP 4234309 A	24-08-1992
		JP 6069943 B	07-09-1994
		KR 9611565 B1	24-08-1996
		MX 9100322 A1	28-02-1992
		US 5246694 A	21-09-1993
		ZA 9105767 A	31-03-1993
US 2001051143	A1	13-12-2001	NONE
US 2002035161	A1	21-03-2002	FR 2787322 A1
			AT 247945 T
			AU 758841 B2
			AU 1664100 A
			BR 9917074 A
			CA 2356366 A1
			CN 1330532 T
			DE 69910835 D1
			DE 69910835 T2
			DK 1143920 T3
			EP 1143920 A1
			ES 2207976 T3
			WO 0037027 A1
			JP 2002532526 T
			NO 20012954 A
			PT 1143920 T
			ZA 200104203 A
US 6607716	B1	19-08-2003	NONE
WO 02074088	A	26-09-2002	CA 2440006 A1
			EP 1367895 A1
			WO 02074088 A1